The Australian legalization of medical cannabis in 2016 launched a flood of companies to the Australian Stock Exchange (ASX), leading investors to ask just which cannabis stocks to watch on the ASX.

Australia’s marijuana sector is young, but with a growing patient base and the possibility of recreational legalization on the horizon, the investment options in the country could prove to be full of opportunity for investors.

Here the Investing News Network takes a look at some of the most pressing influences on the Australian cannabis space and some stocks in the market available for investors.

Cannabis Stocks to Watch on the ASX: What’s affecting share prices on the ASX?

The global cannabis space has been hit hard over the summer of 2019 and the ASX bore some of the brunt as well.

Though Australia is an attractive industry, some experts have expressed hesitation about just how quickly the medical cannabis market has grown in the country and the next steps for the industry.

In a note to investors shared on November 12, Canaccord Genuity Australian equity analysts Cameron Bell and Matthijs Smith said the Australian cannabis industry is a case of “smoke without fire,” adding that Canaccord’s Australian Cannabis Index dropped about 40 percent over the course of four months.

There have also been some leading cannabis public firms that have decided to alter their operations in Australia.

In October, Canopy Growth (NYSE:CGC,TSX:WEED), Cronos Group (NASDAQ:CRON,TSX:CRON) and Aphria (NYSE:APHA,TSX:APHA) all confirmed significant changes to their Australian operations.

The shift included a 37 million share sell-off of the stake in Althea Group Holdings (ASX:AGH) held by Aphria.

Canopy Growth ended the three-year relationship between itself and Australian marijuana firm AusCann Group Holdings (ASX:AC8) when it announced the sale of its 13.2 percent interest in the company on October 15. Canopy Growth shook off over 42 million shares in the sell-off.

On a more positive note, the recent legalization of cannabis in Australia Capital Territory could usher in a new wave of opportunity for cannabis firms as well as more international investment.

Patient numbers have also been up as of late. In its report from Q3 2019, cannabis research firm FreshLeaf Analytics said the patient approval rate increased exponentially in 2019, with almost 30,000 new patient approvals going forward.

FreshLeaf also noted an increase of products in the market to 76 available from the 54 reported in the first quarter of 2019, upping product competition.

Cannabis Stocks to Watch on the ASX: Stocks worth watching in 2020

Here INN offers a closer look at some of the cannabis stocks to watch on the ASX, per largest market capitalization to date and included in the Canaccord Australian cannabis index.

EcoFibre (ASX:EOF)

Market cap: AU$1.1 billion

We kick off our list with the biggest cannabis stock on the ASX by far, EcoFibre.

The New South Wales-based firm has it hands in industrial hemp, boasting over 300 landraces of cannabis from over 25 countries globally, including hemp cultivation in the US.

EcoFibre works through multiple businesses that cover everything from high-quality hemp extracts for pharmaceutical use to hemp-based textiles to hemp food products, including hemp flour and hemp protein powder.

In October, the firm got a nod from the NASDAQ after the exchange brought EcoFibre into the Nasdaq International Designation program under the symbol “EOFBF.” Though the program is over-the-counter, non-US companies can use it to increase their visibility to American investors.

In terms of its medical research, EcoFibre released the results of a cannabidiol (CBD) pain study conducted through Ananda Health, one of its core businesses. The study found that 53 percent of patients who had originally used opioids to manage pain reduced their opioid usage after adding Ananda Heath’s full spectrum hemp extract to their treatment regimen.

In its financial report for its fiscal 2019 year, EcoFibre reported a 519 percent increase in revenue from 2018 to AU$35.6 million. Its products are currently sold in 3,200 independent pharmacies in the US.

Elixinol Global (ASX:EXL,OTCQX:ELLXF)

Market cap: AU$151.7 million

While the New South Wales-based company is listed on the ASX, it has operations across the world, including its subsidiary Elixinol USA, a manufacturer of industrial hemp products such as hemp-infused skincare and hemp dietary supplements in Colorado.

In Q2 2019, the firm reported 18 percent quarter-over-quarter revenue increases to AU$9.9 million. Elixinol Global also expanded its presence in the US marijuana industry after it was awarded a CBD Processor Authorization by the New York State Department of Agriculture Markets.

Apart from its work in North America, Elixinol Global’s Dutch subsidiary, Elixinol BV, signed a distribution agreement with Harmonia Life Oy, which will sell Elixinol Global branded marijuana products through retail channels in Finland over the next five years.

Elixinol Global’s European expansion doesn’t stop there. The company is using its Dutch operations to partner up with 25th Group and leverage its retail channels in Belgium and Luxembourg, the latter of which is seeking to be the first country in Europe to legalize recreational marijuana. Similarly to the Harmonia Life Oy deal, the two countries will be supplied with Elixinol Global branded medical cannabis products over the next five years. The deal also gives Elixinol Global access to retailers in the Netherlands and Switzerland.

Elixinol Global also has its hands in CBD pet care. In August, the firm announced a partnership with Altmed Pets, which trades as Pet Releaf. The deal with the pet CBD company comes with the purchase of US$18 million worth of marijuana products over 18 months. Elixinol also gets a 25 percent equity interest in Pet Releaf.

Botanix Pharmaceuticals (ASX:BDA)

Market cap: AU$96.7 million

Clinical stage CBD company Botanix Pharmaceuticals has a particular focus on treating skin diseases, including acne, psoriasis, dermatitis and rosacea, with a transdermal delivery system.

However, the Western Australia-based company also has an interest in using CBD. In fact, the firm is preparing the first human trials of a proprietary drug system that delivers synthetic CBD-based medicines to the skin.

Botanix Pharmaceuticals recently partnered up with pharmaceutical-grade CBD provider Purisys in a supply agreement that covers Botanix’s needs for synthetic CBD as it continues its clinical trials.

The company’s research efforts got a boost from an innovation grant it was awarded from the government’s AusIndustry division. The new funding will go toward Botanix’s medical chemistry program, which aims to isolate new synthetic versions of CBD and look into the possible antimicrobial properties of the drug.

Althea Group Holdings (ASX:AGH)

Market cap: AU$94.58 million

Althea has seen massive growth in its patient base. The firm announced it was serving 3,000 patients by the end of October — a big jump from the 127 patients it was servicing in October last year — and it remains optimistic it will hit 4,000 patients by the end of 2019.

Althea has the benefit of having an online hub, Concierge, that serves both medical practitioners and medical marijuana patients.

Healthcare workers can use Concierge to access patient treatment plans, and patients get the chance to record their own thoughts about their personal treatment using the hub.

In November, the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE) and Althea got together for ACRE’s clinical cannabinoid cancer trial in New South Wales. Althea, along with other marijuana suppliers, will offer its products as a part of the trial.

In terms of its work outside of Australia, Althea is focusing its international operations in Germany, a medical marijuana market in Europe that some experts say could be one of the largest in the world. Through a memorandum of understanding with global pharmaceutical wholesaler Nimbus Health, Althea plans to use nimbus health’s pharmacy network to distribute its products across the western European country.

Adding on to its retail moves in Germany, Althea will also be developing a Concierge platform for the German market to “help fill a gap in the German market which, despite being advanced in terms of patient numbers, lacks educational initiatives focused on clinical evidence and patient access to medicinal cannabis,” the company said.

Medlab Clinical (ASX:MDC)

Market cap: AU$79.7 million

Medical research and development company Medlab Clinical seeks to use medical marijuana in creating new bio-therapeutics medicines to address chronic ailments such as kidney disease and prediabetes.

Sean Hall, CEO of Medlab, said their work aims to service the global medical marijuana industry and help ease chronic health concerns.

“Global population trends in chronic disease prevalence are reporting increasing numbers of patients diagnosed with various chronic diseases and an acceleration in disease severity,” he said.

To tackle those concerns, Medlab has worked through five core research programs all trying to take advantage of cannabis’ therapeutic benefits.

Recently, Medlab reported a record-breaking month for income generation and medication sales. The firm’s US operations also received its first export order for its proprietary NanoCBD product to Hong Kong.

Speaking of the US, Medlab also plans to take a share of the American marijuana space after signing an agreement with manufacturer ANC that will allow it to distribute its nutraceutical products to the North American country.

Total revenue for its fiscal 2019 year was AU$8.1 million, compared to the AU$5.5 million generated in 2018. Medlab had AU$19.1 million in assets at the end of its fiscal 2019 year.

Cannabis Stocks to Watch on the ASX: Investor takeaway

The marijuana space in Australia is still attempting to find its footing at the global landscape, and investors have their pickings when it comes to which cannabis stocks to watch on the ASX market.

The rise of medical cannabis, however, does pose an interesting opportunity for investors who want to pursue diversifying plays in the at-large cannabis sector.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer (“COO”). As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling.

This press release features multimedia. View the full release here:

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (“ HempFusion ” or the “ Company ”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its wholly owned subsidiary, Probulin Probiotics, LLC (“ Probulin ”), has increased its product selection in certain brick and mortar locations and expanded its distribution on Amazon through a unique eCommerce store within the Amazon platform. The broader product selection is available in major brick and mortar stores including Sprouts and Fresh Thyme and includes the Company’s new Probulin Total Care Immune product.

This press release features multimedia. View the full release here:

Keep reading... Show less

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to report third party confirmatory studies that the active ingredient in MustGrow’s mustard plant-based technology, Allyl Isothiocyanate (“AITC”), has a positive impact on soil health, contributing to the environmental and ecological security of both our plant-based food supply and the planet. Application of natural AITC returns organic plant material to the soil through its pre-plant treatment process as a potential alternative to using synthetic chemicals.

Soil micro-organisms play an important role in soil fertility and plant health, contributing to natural soil processes including the formation of organic matter and nutrient transformation. Human activities, including chemical pesticide use, can adversely impact the soil microbial diversity and structure.

Keep reading... Show less

Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), today announced that its subsidiary CannaCure Corp. (“CannaCure”) has entered into a binding letter of intent with Entourage Participações S.A. (“Entourage Phytolab”) for a three-year extraction and finished product supply agreement (the “Agreement”) for the distribution of pharmaceutical products in Brazil.

Under the terms of the Agreement, Heritage will supply to Entourage Phytolab, hemp-derived CBD dominant extract, cannabis-derived THC dominant extract, and hemp-derived CBD 25 mg softgels and cannabis-derived THC dominant 2.5 and 5.0 mg softgels.

Keep reading... Show less

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) Is pleased to announce its partially owned subsidiary NeonMind (CSE: NEON) (“NeonMind”) has common shares now trading on the Frankfurt Stock Exchange (the “FSE”) under the symbol “6UF”. As a result, NeonMind’s common shares are now cross-listed on the Canadian Securities Exchange and the FSE. Shares of Better Plant are available on the FSE under the symbol “YG3”.

Cannot view this image? Visit:

Keep reading... Show less